This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.
PRIMARY OBJECTIVE: I. To determine the patient's reported preference for cancer pain improvement with opioids, opioids with delta-9-tetrahydrocannabinol (THC)-marijuana and/or opioids with cannabidiol (CBD). SECONDARY OBJECTIVES: I. To determine the association between perception of cancer-related symptom relief and use of THC-marijuana and/or CBD. II. To compare patient perception of THC-marijuana and/or CBD versus (vs.) cancer treatments in treatment of cancer. III. To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD. IV. To evaluate patient reported concerns while using THC-marijuana and/or CBD. V. To evaluate patient attitude of dosing, forms and use of THC-marijuana and/or CBD. VI. To evaluate demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD. VII. To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state. VIII. To explore the patient reported preference of THC-marijuana and CBD for cancer pain and symptom relief of patients in a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson. OUTLINE: Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
Study Type
OBSERVATIONAL
Enrollment
200
Medical records reviewed
Complete questionnaires
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
M D Anderson Cancer Center
Houston, Texas, United States
Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief
Will be calculated and reported along with a 95% confidence interval.
Time frame: through study completion, an average of 1 year
Perception of cancer-related symptom relief
Will be associated with use of THC-Marijuana and/or CBD. Will be evaluated by generalized linear mixed models to account for the dependency among those patients who have used/are using both.
Time frame: through study completion, an average of 1 year
Patient perception of THC-marijuana and/or CBD
Compared to cancer treatments in treatment of cancer. Will be evaluated by generalized linear mixed models to account for the dependency among those patients who have used/are using both.
Time frame: through study completion, an average of 1 year
To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD
Patient reported outcomes will be summarized by frequency and proportion.
Time frame: through study completion, an average of 1 year
To evaluate patient reported concerns while using THC-marijuana and/or CBD
Patient reported outcomes will be summarized by frequency and proportion.
Time frame: through study completion, an average of 1 year
Patient attitude of dosing, forms and use of THC-marijuana and/or CBD
Patient reported outcomes will be summarized by frequency and proportion.
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD
Will be evaluated by Wilcoxon rank sum (Kruskal-Wallis) test or chi-square (Fisher's exact) test, when appropriate. To further evaluate these associations, univariate and multivariable logistic regression models will be fitted. Multiple comparisons will be adjusted where appropriate.
Time frame: through study completion, an average of 1 year
To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state.
Differences will be explored.
Time frame: through study completion, an average of 1 year
Patient reported preference of THC-Marijuana and CBD for cancer pain and symptom relief of patients
Will be explored between a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson. Will be evaluated by Wilcoxon rank sum (Kruskal-Wallis) test or chi-square (Fisher's exact) test, when appropriate. To further evaluate these associations, univariate and multivariable logistic regression models will be fitted. Multiple comparisons will be adjusted where appropriate.
Time frame: through study completion, an average of 1 year